Cancer-specific ligands identified from screening of peptide-display libraries

Current Pharmaceutical Design

Volumn 10, Issue 19, 2004, Pages 2335-2343

  Mori, T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Diagnostics; Library; cancer; Peptide; Phage display; Targeting; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CELL SURFACE PROTEIN; CHIMERIC PROTEIN; CYCLOPEPTIDE; DOXORUBICIN; ERYTHROPOIETIN RECEPTOR AGONIST; FIBROBLAST GROWTH FACTOR RECEPTOR AGONIST; GFE 1 PEPTIDE; K237 PEPTIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E2 15; NONAPEPTIDE; PEPTIDE LIBRARY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNTHETIC PEPTIDE; TACHYPLESIN; THROMBOPOIETIN RECEPTOR AGONIST; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

BONE MARROW TOXICITY; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COMBINATORIAL LIBRARY; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; GENE THERAPY; HUMAN; IMAGING SYSTEM; LIVER TOXICITY; MOLECULAR BIOLOGY; MOLECULAR SIZE; NANOTECHNOLOGY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMANS; LIGANDS; NEOPLASMS; PEPTIDE LIBRARY; PEPTIDES; RECEPTORS, CELL SURFACE;

EID: 3042825003     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383944     Document Type: Review

References (103)

1. Milenic DE. Monoclonal antibody-based therapy strategies: providing options for the cancer patient. Curr Pharm Des 2002; 8: 1749-64.
2. Hudson PJ, Souriau C. Recombinant antibodies for cancer diagnosis and therapy. Expert Opin Biol Ther 2001; 1: 845-55.
3. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003; 52: 281-96.
4. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003; 52: 328-37.
5. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995; 28: 126-42.
6. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers 2002; 66: 184-99.
7. Nilsson F, Tarli L, Viti F, Neri D. The use of phage display for the development of tumour targeting agents. Adv Drug Deliv Rev 2000; 43: 165-96.
8. Langer M, Beck-Sickinger AG. Peptides as carrier for tumor diagnosis and treatment. Curr Med Chem Anti-Canc Agents 2001; 1: 71-93.
9. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002; 66: 161-83.
10. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999; 141: 1-14.
11. Lam KS. Treatment of B-cell lymphoma using peptides. A novel concept. West J Med 1993; 158: 475-9.
12. Lam KS. Application of combinatorial library methods in cancer research and drug discovery. Anticancer Drug Des 1997; 12: 145-67.
13. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380: 364-6.
14. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998; 102: 430-7.
15. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-80.
16. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997; 15: 542-6.
17. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999; 17: 768-74.
18. Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 1999; 59: 2869-74.
19. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999; 5: 1032-8.
20. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228: 1315-7.
21. Castagnoli L, Zucconi A, Quondam M, Rossi M, Vaccaro P, Panni S, et al. Alternative bacteriophage display systems. Comb Chem High Throughput Screen 2001; 4: 121-33.
22. Smith GP, Petrenko VA. Phage Display. Chem Rev 1997; 97: 391-410.
23. Smothers JF, Henikoff S, Carter P. Tech.Sight. Phage display. Affinity selection from biological libraries. Science 2002; 298: 621-2.
24. Willats WG. Phage display: practicalities and prospects. Plant Mol Biol 2002; 50: 837-54.
25. Adda CG, Anders RF, Tilley L. Foley M. Random sequence libraries displayed on phage: identification of biologically important molecules. Comb Chem High Throughput Screen 2002; 5: 1-14.
26. Johnsson K, Ge L. Phage display of combinatorial peptide and protein libraries and their applications in biology and chemistry. Curr Top Microbiol Immunol 1999; 243: 87-105.
27. Brown KC. New approaches for cell-specific targeting: identification of cell-selective peptides from combinatorial libraries. Curr Opin Chem Biol 2000; 4: 16-21.
28. Hartley O. The use of phage display in the study of receptors and their ligands. J Recept Signal Transduct Res 2002; 22: 373-92.
29. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996; 273: 458-64.
30. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997; 276: 1696-9.
31. Ballinger MD, Shyamala V, Forrest LD, Deuter-Reinhard M, Doyle LV, Wang JX, et al. Semirational design of a potent, artificial agonist of fibroblast growth factor receptors. Nat Biotechnol 1999; 17: 1199-204.
32. Renschler MF, Bhatt RR, Dower WJ, Levy R. Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. Proc Natl Acad Sci USA 1994; 91: 3623-7.
33. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 1995; 13: 265-70.
34. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-13.
35. Wickham TJ, Tzeng E, Shears LL, 2nd, Roelvink PW, Li Y, Lee GM, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-9.
36. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol 1994; 124: 373-80.
37. Murayama O, Nishida H, Sekiguchi K. Novel peptide ligands for integrin alpha 6 beta 1 selected from a phage display library. J Biochem (Tokyo) 1996; 120: 445-51.
38. Koivunen E, Ranta TM, Annila A, Taube S, Uppala A, Jokinen M, et al. Inhibition of beta(2) integrin-mediated leukocyte cell adhesion by leucine-leucine-glycine motif-containing peptides. J Cell Biol 2001; 153: 905-16.
39. Szecsi PB, Riise E, Roslund LB, Engberg J, Turesson I, Buhl L, et al. Identification of patient-specific peptides for detection of M-proteins and myeloma cells. Br J Haematol 1999; 107: 357-64.
40. Wu P, Leinonen J, Koivunen E, Lankinen H, Stenman UH. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem 2000; 267: 6212-20.
41. Fukuda MN, Ohyama C, Lowitz K, Matsuo O, Pasqualini R, Ruoslahti E, et al. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res 2000; 60: 450-6.
42. Venkatesh N, Zaltsman Y, Somjen D, Gayer B, Boopathi E, Kasher R, et al. A synthetic peptide with estrogen-like activity derived from a phage-display peptide library. Peptides 2002; 23: 573-80.
43. Buhl L, Szecsi PB, Gisselo GG, Schafer-Nielsen C. Surface immunoglobulin on B lymphocytes as a potential target for specific peptide ligands in chronic lymphocytic leukaemia. Br J Haematol 2002; 116: 549-54.
44. Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, et al. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem 2002; 277: 43137-42.
45. Deshayes K, Schaffer ML, Skelton NJ, Nakamura GR, Kadkhodayan S, Sidhu SS. Rapid identification of small binding motifs with high-throughput phage display: discovery of peptidic antagonists of IGF-1 function. Chem Biol 2002; 9: 495-505.
46. Basmaciogullari S, Babcock GJ, Van Ryk D, Wojtowicz W, Sodroski J. Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding. J Virol 2002; 76: 10791-800.
47. Babcock GJ, Mirzabekov T, Wojtowicz W, Sodroski J. Ligand binding characteristics of CXCR4 incorporated into paramagnetic proteoliposomes. J Biol Chem 2001; 276: 38433-40.
48. Mirzabekov T, Kontos H, Farzan M, Marasco W, Sodroski J. Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol 2000; 18: 649-54.
49. Grundner C, Mirzabekov T, Sodroski J, Wyatt R. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J Virol 2002; 76: 3511-21.
50. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med 1996; 2: 299-305.
51. Zhang J, Spring H, Schwab M. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett 2001; 171: 153-64.
52. Ivanenkov VV, Felici F, Menon AG. Targeted delivery of multivalent phage display vectors into mammalian cells. Biochim Biophys Acta 1999; 1448: 463-72.
53. Maruta F, Parker AL, Fisher KD, Hallissey MT, Ismail T, Rowlands DC, et al. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther 2002; 9: 543-52.
54. Giordano RJ, Cardo-Vila M, Lahdenranta J, Pasqualini R, Arap W. Biopanning and rapid analysis of selective interactive ligands. Nat Med 2001; 7: 1249-53.
55. Romanov VI, Durand DB, Petrenko VA. Phage display selection of peptides that affect prostate carcinoma cells attachment and invasion. Prostate 2001; 47: 239-51.
56. Binetruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. Embo J 2000; 19: 1525-33.
57. Rasmussen UB, Schreiber V, Schultz H, Mischler F, Schughart K. Tumor cell-targeting by phage-displayed peptides. Cancer Gene Ther 2002; 9: 606-12.
58. Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci USA 1994; 91: 7129-33.
59. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 2002; 99: 1527-31.
60. Essler M Ruoslahti E. Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci USA 2002; 99: 2252-7.
61. Samoylova TI, Smith BF. Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve 1999; 22: 460-6.
62. Kennel SJ, Mirzadeh S, Hurst GB, Foote LJ, Lankford TK, Glowienka KA, et al. Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors. Nucl Med Biol 2000; 27: 815-25.
63. Kolonin M, Pasqualini R, Arap W. Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol 2001; 5: 308-13.
64. Ruoslahti E, Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol 2000; 18: 813-27.
65. Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 2000; 10: 435-42.
66. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 2002; 6: 399-404.
67. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60: 722-7.
68. Rajotte D, Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J Biol Chem 1999; 274: 11593-8.
69. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002; 8: 121-7.
70. Krag DN, Fuller SP, Oligino L, Pero SC, Weaver DL, Soden AL, et al. Phage-displayed random peptide libraries in mice: toxicity after serial panning. Cancer Chemother Pharmacol 2002; 50: 325-32.
71. Maruta F, Parker AL, Fisher KD, Murray PG, Kerr DJ, Seymour LW. Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. J Drug Target 2003; 11: 53-9.
72. Ardelt PU, Wood CG, Chen L, Mintz PJ, Moya C, Arap MA, et al. Targeting urothelium: ex vivo assay standardization and selection of internalizing ligands. J Urol 2003; 169: 1535-40.
73. Audige A, Frick C, Frey FJ, Mazzucchelli L, Odermatt A. Selection of peptide ligands binding to the basolateral cell surface of proximal convoluted tubules. Kidney Int 2002; 61: 342-8.
74. Odermatt A, Audige A, Frick C, Vogt B, Frev BM, Frey FJ, et al. Identification of receptor ligands by screening phage-display peptide libraries ex vivo on microdissected kidney tubules. J Am Soc Nephrol 2001; 12: 308-16.
75. Chen Y, Xu X, Hong S, Chen J, Liu N, Underhill CB, et al. RGD-Tachyplesin inhibits tumor growth. Cancer Res 2001; 61: 2434-8.
76. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000; 18: 1185-90.
77. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001; 42: 326-36.
78. Niemeyer CM. Nanoparticles, Proteins, and Nucleic Acids: Biotechnology Meets Materials Science. Angewandte Chemie International Edition 2001; 40: 4128-58.
79. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 2002; 99: 12617-21.
80. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001; 3: 964-75.
81. Liu L, Anderson WF, Beart RW, Gordon EM, Hall FL. Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. J Virol 2000; 74: 5320-8.
82. Trepel M, Grifman M, Weitzman MD, Pasqualini R. Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum Gene Ther 2000; 11: 1971-81.
83. Nicklin SA, White SJ, Watkins SJ, Hawkins RE, Baker AH. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000; 102: 231-7.
84. Nicklin SA, Von Seggern DJ, Work LM, Pek DC, Dominiczak AF, Nemerow GR, et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001; 4: 534-42.
85. Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U, et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001; 4: 174-81.
86. Hart SL, Knight AM, Harbottle RP, Mistry A, Hunger HD, Cutler DF, et al. Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide. J Biol Chem 1994; 269: 12468-74.
87. Monaci P, Urbanelli L, Fontana L. Phage as gene delivery vectors. Curr Opin Mol Ther 2001; 3: 159-69.
88. Uppala A Koivunen E. Targeting of phage display vectors to mammalian cells. Comb Chem High Throughput Screen 2000; 3: 373-92.
89. Molenaar TJ, Michon I, de Haas SA, van Berkel TJ, Kuiper J, Biessen EA. Uptake and processing of modified bacteriophage M13 in mice: implications for phage display. Virology 2002; 293: 182-91.
90. Cunningham BC. Wells JA. Minimized proteins. Curr Opin Struct Biol 1997; 7: 457-62.
91. Kay BK, Kurakin AV, Hyde-DeRuyscher R. From peptides to drugs via phage display. Drug Discovery Today 1998; 3: 370-8.
92. Eichler J, Appel JR, Blondelle SE, Dooley CT, Dorner B, Ostresh JM, et al. Peptide, peptidomimetic, and organic synthetic combinatorial libraries. Med Res Rev 1995; 15: 481-96.
93. Adessi C, Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem 2002; 9: 963-78.
94. Patch JA, Barron AE. Mimicry of bioactive peptides via non-natural, sequence-specific peptidomimetic oligomers. Curr Opin Chem Biol 2002; 6: 872-7.
95. Kieber-Emmons T, Murali R, Greene MI. Therapeutic peptides and peptidomimetics. Curr Opin Biotechnol 1997; 8: 435-41.
96. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
97. Schumacher TN, Mayr LM, Minor DL Jr, Milhollen MA, Burgess MW, Kim PS. Identification of D-peptide ligands through mirror-image phage display. Science 1996; 271: 1854-7.
98. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999; 99: 103-15.
99. Mehl RA, Anderson JC, Santoro SW, Wang L, Martin AB, King DS, et al. Generation of a bacterium with a 21 amino acid genetic code. J Am Chem Soc 2003; 125: 935-9.
100. Wang L Schultz PG. Expanding the genetic code. Chem Commun (Camb) 2002; 1-11.
101. Ast G. Drug-targeting strategies for prostate cancer. Curr Pharm Design 2003; 9(6): 455-66.
102. Lee KH. Development of short antimicrobial peptides derived from host defense peptides or by combinatorial libraries. Curr Pharm Design 2002; 8(9): 795-813.
103. Richardson PL. The determination and use of optimized protease substrates in drug discovery and development. Curr Pharm Design 2002; 8(28): 2559-81.